Triple-Negative Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Interestingly, a novel link between BRCA1 status and miRNA expression level was identified through miR-96 and miR-10b that were very important discriminators between TNBC with mutated BRCA1 and TNBC with wild type BRCA1.
|
31736084 |
2020 |
Triple-Negative Breast Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Pretreatment with a RAD6-selective inhibitor, SMI#9, enhanced cisplatin chemosensitivity of BRCA1 wild-type and mutant TNBCs.
|
31639439 |
2020 |
Triple-Negative Breast Carcinoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
We found that BRCA1 promoter methylation in peripheral blood cells is associated with approximately five times greater risk of TNBC.
|
31469414 |
2020 |
Triple-Negative Breast Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Most BRCA1 carriers (73%) had triple-negative breast cancer; whereas most BRCA2 carriers (72%) had hormone receptor-positive tumors.
|
31581314 |
2020 |
Triple-Negative Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we sought to dissect the mechanisms underlying PARP inhibitor-induced changes in the tumor microenvironment of BRCA1-deficient triple-negative breast cancer (TNBC).
|
31015319 |
2019 |
Triple-Negative Breast Carcinoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
In order to investigate if aberrant promoter methylation of p16, BRCA1 and RASSF1A genes contributes to biological behavior of triple-negative breast cancer (TNBC), marked as the most aggressive phenotype of breast cancer, we compared the hypermethylation pattern between TNBC and ER+PR+Her2- breast cancer.
|
30003738 |
2019 |
Triple-Negative Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
A subset of BRCA1-deficient TNBC cells develop resistance to PARPi by downregulating EMI1 and restoring RAD51-dependent HRR.
|
30554948 |
2019 |
Triple-Negative Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Germline BRCA1/2 prevalence is relatively low in sporadic triple-negative breast cancer (TNBC).
|
30630526 |
2019 |
Triple-Negative Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
As a result, treatment with GO-203 synergistically sensitized both mutant and wild-type BRCA1 TNBC cells to the PARP inhibitor olaparib.
|
30824588 |
2019 |
Triple-Negative Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the present work, we report for the first time the therapeutic potential of talazoparib (BMN 673)-SLNs for the treatment of BRCA1 deficient Triple Negative Breast Cancer (TNBC).
|
31113350 |
2019 |
Triple-Negative Breast Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
From among 1628 women with TNBC who underwent surgery at Samsung Medical Center (SMC) between Jul 2008 and Jan 2016, 999 samples were available in the SMC biobank for testing germline BRCA 1/2 mutations using next-generation DNA sequencing.
|
30350268 |
2019 |
Triple-Negative Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Altogether, the present study confirms that BET proteins directly regulate the homologous recombination pathway and their inhibition induced a BRCAness phenotype in BRCA1 wild-type TNBC cells.
|
30259975 |
2019 |
Triple-Negative Breast Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Consequently, targeted therapies based on the interaction of PI3K inhibition with BRCA1 mutations or HR deficiency in TNBC may be a promising strategy for the treatment of patients with TNBC.
|
31804921 |
2019 |
Triple-Negative Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, more recent evidence showed a similar genomic profile between BRCA1-deficient TNBCs and hormone-receptor-positive tumors.
|
30683142 |
2019 |
Triple-Negative Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Molecular mechanism of triple-negative breast cancer-associated BRCA1 and the identification of signaling pathways.
|
30854067 |
2019 |
Triple-Negative Breast Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Influence of BRCA1 Germline Mutations in the Somatic Mutational Burden of Triple-Negative Breast Cancer.
|
31419696 |
2019 |
Triple-Negative Breast Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The objective of the present study was to elucidate the effect of BMN 673 (talozoparib) on BRCA1 mutant (HCC1937) and wild-type (MDA-MB-231) triple negative breast cancer (TNBC).
|
30672063 |
2019 |
Triple-Negative Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We demonstrated that clinical PARPi, including olaparib and rucaparib, have cell-autonomous immunomodulatory properties in ERCC1-defective NSCLC and BRCA1-defective triple-negative breast cancer (TNBC) cells.
|
30589644 |
2019 |
Triple-Negative Breast Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A higher frequency for BRCA1 mutations was observed in patients with triple-negative breast cancer than in those with non-triple-negative breast cancer (12.3% vs. 2.5%, p = 0.004).
|
30968603 |
2019 |
Triple-Negative Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Further, a synergistic action of quercetin and curcumin was observed in modulating the BRCA1 level and in inhibiting the cell survival and migration of TNBC cell lines.
|
30478904 |
2019 |
Triple-Negative Breast Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We used PDX models from triple-negative breast cancer (TNBC) with neoadjuvant chemotherapy and/or germline BRCA1 mutations in chemosensitivity tests.
|
31821346 |
2019 |
Triple-Negative Breast Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
This variant was previously identified to be associated with the susceptibility of breast cancer with BRCA1 mutation triple negative breast cancer.
|
31509622 |
2019 |
Triple-Negative Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Investigators are building on these results by designing novel clinical trials for patients with BRCA1/2-deficient tumors and/or triple-negative breast cancer.
|
30789866 |
2019 |
Triple-Negative Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The higher incidence of TNBC in certain populations such as young women and/or women of African ancestry and a unique pathological phenotype shared between TNBC and BRCA1-deficient tumors suggest that TNBC may be inherited through germline mutations.
|
31379942 |
2019 |
Triple-Negative Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We report that VEGF-NRP2 promote homologous recombination (HR) in BRCA1 wild-type TNBC cells by contributing to the expression and function of Rad51, an essential enzyme in the HR pathway that mediates efficient DNA double-strand break repair.
|
31235595 |
2019 |